InsidersTradesSigma
Track the 康泰生物 stock price and the full management transaction log of the company, a listed issuer based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 康泰生物 has logged 4 public disclosures. Market capitalisation: €13.8bn. The latest transaction was disclosed on 31 January 2023 (Purchase). Among the most active insiders: 陶瑾. All data is free.
4
Insider Decl.
n/a
Thresholds
€655,787
3 ops.
Buy Volume
€3m
1 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,632 of 29,064 companies
40.3
score / 100
Value33
Quality48
FCF yld2.2%
Earn yld0.5%
EV/EBITDA27.9x
ROE0.8%
Gross mgn75%
Net mgn2.6%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 January 2023
关于 康泰生物
康泰生物是一家在XSHE市场上市的健康和制药领域的公司。它专注于生物和医药产品的开发和生产。